TRex Bio, Inc. Form SCHEDULE 13D — Oct 16, 2026
Eli Lilly filed a Schedule 13D disclosing beneficial ownership of 5,480,872 shares of TRex Bio common stock, approximately 19.9% of the 27,577,535 shares outstanding following TRex Bio's IPO. The stake consists of shares from the conversion of Series A and Series B redeemable convertible preferred stock plus 875,000 shares purchased in the IPO at $14.00 per share for roughly $12.3 million.
Key figures
- Deal Value Usd
- 12300000
- Lockup days
- 180
- Percent of class
- 19.9%
- Ipo price per share
- 14
- Shares outstanding total
- 27577535
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.